CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D058345: Asymptomatic Infections NIH

(Synonyms: Asymptomatic Infections)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug1280 Ivermectin Pill Wiki 1.00
drug613 Combined ART/hydroxychloroquine Wiki 1.00
drug527 Carotid Artery Reactivity Testing Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Comparative Efficacy of Ivermectin Versus Combination of Hydroxychloroquine Plus Darunavir/ Ritonavir for Shortening Duration of SARS-CoV2 Detection From Respiratory Secretion Among Asymptomatic or Afebrile COVID-19 Infection

This is an open label randomised controlled study of oral ivermectin (600 mcg/kg/d* 3 day) versus combined of hydroxychloroquine plus darunavir/ ritonavir for 5 days treatment among asymptomatic carrier of SAR-CoV2 adult Thai population. Outcomes include safety and duration of detectable of SAR-CoV2 in nasopharyngeal/ throat (NP) swab by polymerase chain reaction amplification (PCR) after treatment. 40-50 patients in each treatment arm is planned, with an interim analysis when approximately 50% of cases is enrolled.

NCT04435587 Asymptomatic Infections SARS-CoV2 Infection Drug: Ivermectin Pill Drug: Combined ART/hydroxychloroquine
MeSH:Infection Communicable Diseases Asymptomatic Infections

Primary Outcomes

Description: Comparison of adverse event rates between treatment arms

Measure: Adverse event rates

Time: after first dose until day 28 of follow up

Description: comparison of median duration for detectable SAR-CoV2 by PCR from NP swab in each arm

Measure: Efficacy for shortening duration of SAR-CoV2 detection by PCR

Time: weekly after treatment until 4th week

Secondary Outcomes

Description: comparison of median duration for total antibody detection in each arm

Measure: Antibody detection rates

Time: weekly after treatment until 4th week


HPO Nodes